Objective: Efficacy or long-term result of metastasectomy for recurrent or metastatic biliary tract carcinoma (BTC) is not well established. We conducted a retrospective review of the outcomes of metastasectomy for recurrent or metastatic BTCs. Methods: The clinicopathological features and outcomes of consecutive patients with BTCs who underwent surgical resection for primary and metastatic disease at a tertiary referral hospital from 2003 to 2013 were reviewed retrospectively. Results: We found 19 eligible patients. Median age of patients was 57 years old (range, 27 to 68 years old), and 11 patients (58%) were female. Primary sites were gallbladder cancer (seven patients, 37%), intrahepatic cholangiocarcinoma (five patients, 26%), distal common bile duct cancer (three patients, 16%), proximal common bile duct cancer (two patients, 11%), and ampulla of Vater cancer (two patients, 11%). Eight patients (42%) had synchronous metastasis, while 11 (58%) had metachronous metastasis. The most common metastatic site was liver (nine patients, 47%), lymph node (nine patients, 47%), and peritoneum (three patients, 16%). Nine patients (47%) achieved R0 resection, while four (21%) and six (32%) patients had R1 and R2 resection, respectively. With a median follow-up period of 26.7 months, the estimated median overall survival (OS) was 18.2 months (95% confidence interval [CI], 13.6 to 22.9 months). Lower Eastern Cooperative Oncology Group performance status (P = 0.023), metachronous metastasis (P= 0.04), absence of lymph node metastasis (P= 0.009), lower numbers of metastatic organs (P< 0.001), normal postoperative carbohydrate antigen 19-9 level (P= 0.034), and time from diagnosis to metastasectomy more than one year (P= 0.019) were identified as prognostic factors for a longer OS after metastasectomy. Conclusion: For recurrent or metastatic BTCs, metastasectomy can be a viable option for selected patients.
INTRODUCTION
Biliary tract carcinomas (BTCs), comprising intrahepatic cholangiocarcinoma (IHCCC), proximal and distal common bile duct cancer (pCBDC and dCBDC), gallbladder cancer (GBC), and ampulla of Vater cancer (AoVC), are relatively rare cancers [1] ; however, high mortality and incidence rates are still evident in some countries, including central and eastern Europe, Japan, Chile, India, and Korea [2] .
Complete surgical resection is the only chance for cure; however, a limited number of patients present with resectable disease.
Unfortunately, even after surgical resection, recurrence is frequently reported. Prognosis for recurrent or metastatic BTC is still poor, with a median overall survival (OS) of around one year, even with the best treatment option [3] .
Metastasectomy, resection of distant metastasis, has been increasingly adopted in some types of cancers, and it is associated with prolonged relapse free survival and even cure in prudently selected patients. Some examples of cancers in which metastasectomy is actively performed are colorectal cancer (hepatic metasta-http://jsms.sch.ac.kr sis and pulmonary metastasis) [4, 5] , soft tissue sarcoma (pulmonary metastasis) [6] , and renal cell carcinoma (pulmonary metastasis) [7] .
Efficacy or long term-result of metastasectomy for recurrent or metastatic BTC is not well established. Aggressive surgical attempts for advanced GBC have been reported several times [8] [9] [10] [11] [12] [13] [14] [15] ; however, most of these reports included patients with locally advanced GBC rather than metastatic GBC. Regarding metastasectomy in BTC, to the best of our knowledge, only a small number of cases involving a very limited number of patients have been reported [16] [17] [18] [19] [20] [21] ; therefore, the efficacy of the surgical resection of metastasis in BTC remains unclear.
Against this background, we retrospectively reviewed the outcomes of metastasectomy for recurrent or metastatic BTC in a single tertiary referral center hospital.
MATERIALS AND METHODS

Materials
The medical records of consecutive patients with BTCs (IHCCC, pCBDC, dCBDC, GBC, and AoVC) who were treated with surgery, chemotherapy, radiotherapy, or best supportive care at a tertiary referral hospital from 2003 to 2013 were reviewed retrospectively.
In these patients, the selection criteria for analysis were as follows:
histologically confirmed BTC; synchronous (M1 according to the American Joint Committee on Cancer 7th edition) or metachronous (recurrent) metastatic disease; and surgical resection of primary and metastatic sites. To be eligible for analysis, patients also had to have proper baseline and follow-up image work-up data before and after metastasectomy. Patients treated with metastasectomy for symptom palliation only were not included in analysis. Table 1 . Median age of patients was 57 years old (range, 27 to 68 years old), and 58% of patients were female. Primary sites were GBC (seven patients, 37%), IHCCC (five patients, 26%), dCBDC (three patients, 16%), pCBDC (two patients, 11%), and AoVC (two patients, 11%), in order. Most patients had adenocarcinoma (95%), eight (42%) had synchronous metastasis, and 11 (58%) had metachronous metastasis. Most patients had good ECOG PS before Values are presented as median (range) or number (%).
Data collection
metastasectomy, as more than 70% had ECOG PS 0-1. The most common metastatic site was liver (nine patients, 47%), lymph node (nine patients, 47%), and peritoneum (in the form of limited peritoneal implantation without evidence of disseminated peritoneal seeding (three patients, 16%).
Outcomes of metastasectomy
The clinical characteristics and outcome of metastasectomy are shown in Table 2 (Fig. 1 ).
Prognostic factors and characteristics of patients with longer overall survival
For patients who achieved R0 or R1 resection, predictive factors for RFS were explored using the log-rank test; however, no clinicopathologic factor was proved to be relevant to better PFS. For all patients who underwent metastasectomy, prognostic factors for OS were also explored. Lower ECOG PS (P = 0.023), metachronous metastasis (P = 0.04), absence of lymph node metastasis (P = 0.009), lower numbers of metastatic organs (P < 0.001), nor- Table 2 . Clinical characteristics and outcomes of metastasectomy (N= 19) No. F, female; GBC, gallbladder cancer; MC, metachronous; CTx, chemotherapy; M, male; dCBDC, distal common bile duct cancer; IHCCC, intrahepatic cholangiocarcinoma; NA, not applicable; pCBDC, proximal common bile duct cancer; SC, synchronous; AoVC, ampulla of Vater cancer; LN, lymph node; CRTx, chemoradiotherapy.
a)
The patient died of fulminant hepatic failure from acute hepatitis B after four cycles of gemcitabine and cisplatin CTx. The best overall response for CTx was stable disease.
(P = 0.034), and TTM more than one year (P = 0.019) were identified as prognostic factors for a longer OS after metastasectomy ( (Fig. 2) .
DISCUSSION
In the current study, we found 19 patients with metastatic or recurrent BTC who underwent metastasectomy. Median OS was 18.2 months (95% CI, 13.6 to 22.9 months), and patients with lower ECOG PS, metachronous metastasis, absence of lymph node metastasis, lower numbers of metastatic organs, normal postoperative CA19-9 level, or TTM more than one year had longer OS after metastasectomy. http://jsms.sch.ac.kr
Previous reports of aggressive surgery in advanced GBC mostly included stage IVA and only a small fraction of stage IVB. It appears that aggressive surgery resulted in long-term survival in a very selected population, if curative resection is possible and number of metastases is limited. [11, 12, 14, 15] . Some reports on metastasectomy for BTC include resection of adrenal metastasis from IHCCC [19] , resection of solitary hepatic recurrence of IHCCC [20] , and resection plus radiotherapy for two patients with locoregional failure of main hepatic duct carcinoma [21] . To date, data are insufficient to draw a conclusion regarding whether or not metastasectomy is helpful for patients with recurrent or metastatic BTC. Recent data on hepatic metastasectomy from colorectal cancer metastasis in the United States and Canada have demonstrated 10-year disease-free survival of 15% to 25%, which is much better than the survival on even the best systemic chemotherapy during that period [22] . Likewise, pulmonary metastasectomy for soft tissue sarcoma achieved a 3-and 5-year OS rate of approximately 45% and 35%, respectively, which is better than that for patients who did not undergo resection [6, 23] . Lessons from such solid malignancies have shed light on the value of surgical resection in metastatic disease from other malignancies, and metastasectomy strategy could be adopted for advanced BTC with caution.
Because there will be sparse chance for conduct of a randomized controlled trial on metastasectomy in BTC, clinicians can make a decision regarding whether or not to perform metastasectomy based on extrapolated criteria from previous reports. In general, metastasectomy is preferred in the following situations: possibility of complete resection, small number of metastatic lesions (single metastasis or oligometastases rather than multiple metastases), no unresectable metastasis in other organs, and good general condition of patient.
In a previous report on aggressive surgery for BTC, some clinicopathologic features were described as good prognostic factors:
low preoperative carcinoembryonic antigen [11] , adjuvant chemotherapy [11] , curative resection [11, 15] , isolated liver metastasis [14] , absence of lymph node metastasis [15] , absence of vascular resection [15] , or absence of hepatoduodenal ligament invasion [15] .
In the current study, patients with good ECOG PS, metachronous metastasis, absence of lymph node metastasis, lower numbers of metastatic organs, normal postoperative CA19-9 level, or TTM more than one year were depicted as good prognostic factors for longer OS after metastasectomy. Patients in the favorable risk group who had four or more good prognostic factors achieved significantly prolonged OS after metastasectomy. We could not perform multivariable analysis due to a small number of included patients; however, we believe that our results can be helpful in suggestion of some future criteria for metastasectomy in BTC.
There have been some suggestions that BTC is not a single entity of disease but a heterogeneous group of diseases with different prognoses [24] and biology [25] according to primary site. Therefore, metastasectomy can have an important role in some diseases while not in others. In addition, after metastasectomy, when visible masses are completely resected, the role of postoperative che- motherapy and/or radiotherapy is not known. In our study, primary site and post-metastasectomy treatment did not affect OS;
however, we could not draw a firm conclusion due to the limitation of this study. In the future, if metastasectomy becomes a treatment option for at least some subsets of patients with advanced BTC, outcome differences among primary sites and the role of postoperative treatment should be verified.
There are several limitations in this study. The current study includes only a small number of patients, consisting of a heterogeneous group. In addition, this is a retrospective cohort study that included patients over many years, so that there could be biases inherent to this type of study. These shortcomings need to be rectified in future studies.
In conclusion, for recurrent or metastatic BTC, metastasectomy can be a viable option for selected patients, particularly those having good performance status and metachronous disease without recurrence of lymph node metastasis more than one year after surgery.
